GlassScriptPhysician profile
Arthur Levene
NPI 1437165784
$14,776.51
in general payments reported to CMS, 2019-2025
34 companies · $705 in 2025
The $705 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,765 · 2020: $283 · 2021: $696 · 2022: $1,399 · 2023: $2,510 · 2024: $2,418 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,666.81 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $1,364.78 | 2022-2025 | Optimizer, Optimizer |
| Boston Scientific Corporation | $1,148.43 | 2019-2025 | Watchman Access System, Watchman Flx, Watchman |
| Astrazeneca Pharmaceuticals LP | $825.67 | 2019-2024 | Farxiga, Andexxa, Lokelma |
| Abbott Laboratories | $814.34 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.47 | 2019-2024 | Jardiance |
| Amgen INC. | $680.83 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $642.69 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $571.34 | 2019-2025 | |
| Cvrx, INC. | $568.82 | 2023-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $364.17 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $237.37 | 2022-2024 | Verquvo |
| Heartflow, INC. | $169.33 | 2021 | |
| Akcea Therapeutics, INC. | $138.61 | 2019-2020 | |
| United Therapeutics Corporation | $124.80 | 2024 | Tyvaso |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $123.27 | 2022-2023 | Assure Wcd |
| Janssen Scientific Affairs, LLC | $94.24 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $93.78 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $45.48 | 2019-2021 | |
| Scpharmaceuticals INC. | $43.29 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $35.87 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $35.78 | 2023 | Arcalyst |
| Portola Pharmaceuticals, LLC | $34.66 | 2019 | |
| Zoll Respicardia, INC. | $34.09 | 2023 | Remede System |
| Esperion Therapeutics, INC. | $32.54 | 2023-2024 | Nexletol |
| Edwards Lifesciences Corporation | $29.83 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $25.39 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $24.16 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $22.69 | 2021 | |
| Daiichi Sankyo INC. | $20.44 | 2024 | Injectafer |
| Gilead Sciences, INC. | $19.71 | 2019 | |
| Vifor Pharma, INC. | $18.75 | 2021 | |
| Ge Healthcare | $17.63 | 2024 | |
| Amarin Pharma, INC. | $17.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Levene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.